GLP1R and obesity disorder: The GLP-1 receptor agonists have been associated with a significant reduction in pancreatic and other obesity-related cancers, likely due to their combined effects on weight loss, improved metabolic and inflammatory profiles, and direct anti-proliferative actions [92].